Natte krant schreef op 8 oktober 2015 17:02:
Bron KBC Securities
Shining the light on cystic fibrosis at US conference
News:
Galapagos will present as much as five posters on its cystic fibrosis program at this week’s North American Cystic Fibrosis Conference (NACFC).
Our View:
The posters will become available on Galapagos’s website following their presentation.
Friday, 9 October 7.30 AM - 8.45 AM
1. Potentiators: how do they impact the fate of CFTR during biogenesis?
Insights are presented on the contribution of GLPG1837 to the rescue of F508del CFTR
2. Insight into the mechanisms of correctors and potentiators
Galapagos and Abbvie developed new tools to better understand the mechanism of action of correctors and potentiators in its CF portfolio
3. Using BLISS analysis to categorize corrector-corrector interactions
Galapagos and AbbVie disclose the usage of a modelling tool to categorize interactions between candidate corrector compounds in their CF program
4. Safety, tolerability and pharmacokinetics of a novel CFTR Potentiator GLPG1837 in healthy volunteers
Galapagos presents safety and tolerability of GLPG1837 in healthy human volunteers, paving the path for the Phase 2 study in Class III mutation patients to start by end 2015.
Saturday, 10 October 7.30 AM - 8.45 AM
5. Novel Potentiators Augment Efficacy of Translational Readthrough in CFTR Nonsense Mutations
Promising pre-clinical data using Galapagos potentiators on Class I (nonsense) CFTR mutations is presented
We remind that Galapagos has a joint collaboration with AbbVIE in its CF program. The true goal of this collaboration is to develop a triple combination therapy build on one potentiator (GLPG1837) and two corrector molecules. The first corrector (referred to as GLPG2222, originating from AbbVie) will start phase 1 testing before YE15 while the second corrector preclinical candidate is due to be selected shortly as well.
Conclusion:
All posters deal with preclinical and laboratory data, except for one which presents the phase 1 data in healthy volunteers on its CF potentiator molecule GLPG1837 which is expected to move into phase 2 by YE15.
Given the huge interest from (specialist) investors in cystic fibrosis, we expect Galapagos to seek the spotlight at this conference to position itself as the competitor for Vertex in the race to the triple CF combo therapy (expected to enter phase 2 in 2017.